# An Extension of SKY-0515 in Participants With Huntington's Disease

> **NCT07537075** · PHASE2,PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Skyhawk Therapeutics, Inc.** · enrollment: 500 (estimated)

## Conditions studied

- Huntington's Disease (HD)

## Interventions

- **DRUG:** SKY-0515

## Key facts

- **NCT ID:** NCT07537075
- **Lead sponsor:** Skyhawk Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-04-10
- **Primary completion:** 2029-12
- **Final completion:** 2029-12
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07537075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07537075, "An Extension of SKY-0515 in Participants With Huntington's Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07537075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*